ATE555115T1 - Neue kristalline und amorphe form einer triazolo(4,5-d)pyrimidin verbindung - Google Patents

Neue kristalline und amorphe form einer triazolo(4,5-d)pyrimidin verbindung

Info

Publication number
ATE555115T1
ATE555115T1 AT04015299T AT04015299T ATE555115T1 AT E555115 T1 ATE555115 T1 AT E555115T1 AT 04015299 T AT04015299 T AT 04015299T AT 04015299 T AT04015299 T AT 04015299T AT E555115 T1 ATE555115 T1 AT E555115T1
Authority
AT
Austria
Prior art keywords
triazolo
amorphous form
pyrimidine compound
new crystalline
crystalline
Prior art date
Application number
AT04015299T
Other languages
English (en)
Inventor
Martin Bohlin
Steve Cosgrove
Bo Lassen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE555115(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE555115T1 publication Critical patent/ATE555115T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04015299T 2000-06-02 2001-05-31 Neue kristalline und amorphe form einer triazolo(4,5-d)pyrimidin verbindung ATE555115T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0013407.2A GB0013407D0 (en) 2000-06-02 2000-06-02 Forms of a chemical compound

Publications (1)

Publication Number Publication Date
ATE555115T1 true ATE555115T1 (de) 2012-05-15

Family

ID=9892841

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01937109T ATE320430T1 (de) 2000-06-02 2001-05-31 Neue kristalline form einer triazolo(4,5- d)pyrimidin-verbindung
AT04015299T ATE555115T1 (de) 2000-06-02 2001-05-31 Neue kristalline und amorphe form einer triazolo(4,5-d)pyrimidin verbindung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01937109T ATE320430T1 (de) 2000-06-02 2001-05-31 Neue kristalline form einer triazolo(4,5- d)pyrimidin-verbindung

Country Status (36)

Country Link
US (3) US20030181469A1 (de)
EP (3) EP2292622A1 (de)
JP (3) JP5036947B2 (de)
KR (1) KR100781864B1 (de)
CN (2) CN1247583C (de)
AR (2) AR032335A1 (de)
AT (2) ATE320430T1 (de)
AU (4) AU6287401A (de)
BG (3) BG65837B1 (de)
BR (1) BR0111328A (de)
CA (1) CA2408596C (de)
CY (1) CY1113047T1 (de)
CZ (2) CZ307468B6 (de)
DE (1) DE60117972T2 (de)
DK (2) DK1289992T3 (de)
EE (1) EE05222B1 (de)
ES (2) ES2259031T3 (de)
GB (1) GB0013407D0 (de)
HK (1) HK1052347B (de)
HU (2) HU230471B1 (de)
IL (4) IL152777A0 (de)
IS (2) IS2609B (de)
MX (1) MXPA02011795A (de)
MY (2) MY140674A (de)
NO (3) NO323780B1 (de)
NZ (1) NZ522638A (de)
PH (1) PH12011000127A1 (de)
PL (2) PL392882A1 (de)
PT (2) PT1493745E (de)
RU (3) RU2325391C2 (de)
SG (1) SG135965A1 (de)
SI (2) SI1289992T1 (de)
SK (1) SK287817B6 (de)
UA (1) UA73181C2 (de)
WO (1) WO2001092262A1 (de)
ZA (1) ZA200209324B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
JP4298212B2 (ja) * 2002-03-29 2009-07-15 大日本印刷株式会社 塩酸エピナスチン高融点型結晶の製造法
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
US7566722B2 (en) * 2006-10-31 2009-07-28 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
CN101743001B (zh) * 2007-04-13 2013-02-06 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
SI2340252T1 (sl) 2008-09-09 2016-02-29 Astrazeneca Ab Postopek priprave (1S-)1-alfa, 2-alfa, 3-beta(1S*,2R*)5-beta))-3-(7-(2-(3,4-difluorofenil)-ciklopropilamino)-5- (propiltio)-3H-1,2,3-triazolo(4,5-D)pirimidin-3-il)-5-(2-hidroksietoksi) ciklopentan-1,2-diola in njegovih vmesnih spojin
WO2011017108A2 (en) 2009-07-27 2011-02-10 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of p2y12 receptor
CN102770434A (zh) * 2009-12-03 2012-11-07 阿斯利康(瑞典)有限公司 三唑并[4,5-d]嘧啶血小板聚集抑制剂的共晶体
ES2548845T3 (es) 2009-12-23 2015-10-21 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico
CZ2011229A3 (cs) 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
EP2714047A1 (de) * 2011-06-01 2014-04-09 AstraZeneca AB Neuer ticagrelor- cokristall
WO2013079589A1 (en) * 2011-11-30 2013-06-06 Actavis Group Ptc Ehf Novel crystalline form of ticagrelor and process for the preparation thereof
US9233966B2 (en) 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
WO2014000719A1 (en) * 2012-06-29 2014-01-03 Zentiva, K.S. Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol
EP2870155B1 (de) 2012-07-04 2016-08-24 LEK Pharmaceuticals d.d. Ticagreloraddukte mit divalenten metallsalzen
CZ2012705A3 (cs) 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
CN103772393B (zh) * 2012-10-18 2017-08-04 博瑞生物医药（苏州）股份有限公司 替卡格雷的晶型及其制备方法
WO2014083139A1 (en) * 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
CN103848836B (zh) * 2012-12-07 2016-08-03 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物及其制备方法
WO2014118808A2 (en) * 2013-02-04 2014-08-07 Hetero Research Foundation Ticagrelor solid dispersion
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
IN2013MU01111A (de) * 2013-03-25 2015-05-01 Glenmark Generics Ltd
CN104098570A (zh) * 2013-04-07 2014-10-15 杭州领业医药科技有限公司 替卡格雷晶型及其制备方法和用途
CN104098572A (zh) * 2013-04-08 2014-10-15 博瑞生物医药技术(苏州)有限公司 替卡格雷共晶型
CN107573333B (zh) * 2013-04-10 2019-10-18 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP2813216A1 (de) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilisiertes amorphes Ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
CN105377240A (zh) 2013-05-29 2016-03-02 拉蒂奥法姆有限责任公司 固体药物剂型
CN106496235A (zh) * 2013-06-03 2017-03-15 杭州领业医药科技有限公司 结晶形态的三唑[4,5‑d]嘧啶化合物及其制备方法和用途
EP3004113A2 (de) * 2013-06-04 2016-04-13 Dr. Reddy's Laboratories Ltd. Herstellung von ticagrelor
EP2816043A1 (de) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Kugelförmige Ticagrelorteilchen
WO2015001489A1 (en) * 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CN104341423B (zh) * 2013-08-02 2017-03-01 上海京新生物医药有限公司 替格瑞洛的一水合物及其制备方法与在制药中的应用
CN104370912A (zh) * 2013-08-13 2015-02-25 开原亨泰制药股份有限公司 替卡格雷多晶型体及其制备方法
WO2015037016A2 (en) * 2013-09-10 2015-03-19 Laurus Labs Private Limited An improved process for the preparation of ticagrelor and intermediates thereof
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104650085A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物化合物
CN103601726B (zh) * 2013-12-02 2016-09-28 浙江大学 两种替格瑞洛药物共晶及其制备方法
CN104710425B (zh) * 2013-12-16 2019-06-14 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛新结晶及其制备方法
CN104650091B (zh) * 2014-01-24 2016-10-05 福州乾正药业有限公司 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
WO2015162537A1 (en) * 2014-04-23 2015-10-29 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ticagrelor
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
CN105315282B (zh) * 2014-07-15 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种制备替卡格雷无定型的方法
WO2016016907A1 (en) * 2014-08-01 2016-02-04 Msn Laboratories Private Limited Novel polymorphs of (1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophenyl) cyclopropyl]amino}-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yi]-5-(2-hydroxvethoxy) cyclopentane-1,2-diol
US10017515B2 (en) 2014-08-11 2018-07-10 Sun Pharmaceutical Industries Limited Stable amorphous ticagrelor and a process for its preparation
CN104193747B (zh) * 2014-08-12 2016-05-11 许彩霞 替卡格雷无定形的制备
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105968113B (zh) * 2015-03-12 2019-06-07 四川海思科制药有限公司 一种三唑并嘧啶衍生物及其应用
WO2017072790A1 (en) * 2015-10-26 2017-05-04 Avra Laboratories Pvt. Ltd. An improved process for synthesis of ticagrelor
WO2017118633A1 (en) * 2016-01-05 2017-07-13 Amneal Pharmaceuticals Company Gmbh Crystalline form of ticagrelor
SG11201808996SA (en) 2016-04-21 2018-11-29 Astrazeneca Ab Orally disintegrating tablets
US10905691B2 (en) 2016-09-09 2021-02-02 Université de Liège Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
EP3292867B1 (de) * 2016-09-09 2019-05-15 Université de Liège Triazolo(4,5-d)pyrimidin-derivate zur vorbeugung und behandlung bakterieller infektionen
KR101916956B1 (ko) 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
WO2018178997A1 (en) 2017-03-31 2018-10-04 Natco Pharma Limited Novel crystalline form of ticagrelor
WO2019127294A1 (zh) * 2017-12-29 2019-07-04 浙江天宇药业股份有限公司 一种纯化替格瑞洛的方法
EP3761965A1 (de) 2018-03-08 2021-01-13 Pharmaceutical Oriented Services Ltd Ticagrelor-containing tablet formulation
WO2020021110A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Pharmaceutical composition of ticagrelor
CN110194771A (zh) * 2019-05-08 2019-09-03 北京济美堂医药研究有限公司 一种替格瑞洛药用ii晶型的制备方法
CN114634489B (zh) * 2022-04-19 2023-07-04 奎马特里克斯有限公司 结晶形式
CN117510508A (zh) * 2023-11-14 2024-02-06 江苏普润生物医药有限公司 一种高纯度ii晶型替格瑞洛的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
FR2687677B1 (fr) * 1992-02-24 1996-10-11 Union Pharma Scient Appl Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
HU221880B1 (hu) * 1995-07-11 2003-02-28 Astrazeneca Ab, Vérlemezke-aggregáció inhibitorok, ezeket tartalmazó gyógyszerkészítmények és előállításuk
ATE213245T1 (de) * 1996-12-20 2002-02-15 Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
TW530058B (en) * 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
ATE305009T1 (de) * 1997-07-25 2005-10-15 Gilead Sciences Inc Nukleotid-analog zusamensetzung und synthese verfahren
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound

Also Published As

Publication number Publication date
MY140674A (en) 2010-01-15
UA73181C2 (en) 2005-06-15
AU2010257449B2 (en) 2012-03-22
AU2007200958A1 (en) 2007-03-29
US20070173518A1 (en) 2007-07-26
BG110440A (bg) 2010-03-31
JP2003535092A (ja) 2003-11-25
NO323780B1 (no) 2007-07-02
AU2007200958B2 (en) 2010-10-07
IS8825A (is) 2009-06-02
EE200200665A (et) 2004-06-15
EP2292622A1 (de) 2011-03-09
NO20025756L (no) 2003-01-24
HK1073101A1 (en) 2005-09-23
JP2014129423A (ja) 2014-07-10
CA2408596C (en) 2010-12-21
MY148652A (en) 2013-05-15
ES2384708T3 (es) 2012-07-11
PL392882A1 (pl) 2011-03-14
US20070293513A1 (en) 2007-12-20
CA2408596A1 (en) 2001-12-06
CN1247583C (zh) 2006-03-29
CN1817883B (zh) 2011-10-05
IS3019B (is) 2020-02-15
AR068086A2 (es) 2009-11-04
JP5684192B2 (ja) 2015-03-11
IL202582A0 (en) 2010-06-30
RU2325391C2 (ru) 2008-05-27
NO20025756D0 (no) 2002-11-29
AU6287401A (en) 2001-12-11
EP1493745A1 (de) 2005-01-05
SG135965A1 (en) 2007-10-29
BG107331A (bg) 2003-07-31
NO20071547L (no) 2003-01-24
HUP0302284A2 (hu) 2003-10-28
US7265124B2 (en) 2007-09-04
ES2259031T3 (es) 2006-09-16
EP1289992A1 (de) 2003-03-12
PT1493745E (pt) 2012-06-28
IL202582A (en) 2012-12-31
EP1493745B2 (de) 2021-05-19
ATE320430T1 (de) 2006-04-15
CN1432018A (zh) 2003-07-23
JP2012149093A (ja) 2012-08-09
MXPA02011795A (es) 2003-04-10
NZ522638A (en) 2004-06-25
PL359172A1 (en) 2004-08-23
RU2418802C2 (ru) 2011-05-20
EP1289992B1 (de) 2006-03-15
US20030181469A1 (en) 2003-09-25
PH12011000127A1 (en) 2016-08-31
BG65837B1 (bg) 2010-02-26
BG66332B1 (bg) 2013-06-28
CY1113047T1 (el) 2016-04-13
IS2609B (is) 2010-04-15
EP1493745B1 (de) 2012-04-25
AR032335A1 (es) 2003-11-05
CZ304347B6 (cs) 2014-03-19
BG111017A (bg) 2011-12-30
DE60117972D1 (de) 2006-05-11
HU229374B1 (en) 2013-11-28
HU230471B1 (hu) 2016-07-28
DE60117972T2 (de) 2006-11-23
AU2001262874B2 (en) 2007-03-22
SK16852002A3 (sk) 2003-08-05
IL152777A0 (en) 2003-06-24
HK1052347B (en) 2006-09-08
HUP0302284A3 (en) 2007-05-29
SI1493745T1 (sl) 2012-08-31
RU2005127356A (ru) 2007-03-10
IL152777A (en) 2008-11-26
EE05222B1 (et) 2009-10-15
AU2010257449A1 (en) 2011-01-20
CN1817883A (zh) 2006-08-16
KR100781864B1 (ko) 2007-12-05
NO20120595L (no) 2003-01-24
CZ20120293A3 (de) 2003-07-16
IL187482A (en) 2010-06-16
DK1493745T3 (da) 2012-07-16
SK287817B6 (sk) 2011-11-04
NO332306B1 (no) 2012-08-20
HK1052347A1 (en) 2003-09-11
DK1289992T3 (da) 2006-07-03
KR20030007829A (ko) 2003-01-23
GB0013407D0 (en) 2000-07-26
NO333289B1 (no) 2013-04-29
IS6623A (is) 2002-11-15
PT1289992E (pt) 2006-07-31
RU2010150799A (ru) 2012-06-20
WO2001092262A1 (en) 2001-12-06
JP5036947B2 (ja) 2012-09-26
CZ307468B6 (cs) 2018-09-26
HUP1300386A2 (en) 2003-10-28
ZA200209324B (en) 2004-02-16
BR0111328A (pt) 2003-06-10
SI1289992T1 (sl) 2006-08-31

Similar Documents

Publication Publication Date Title
ATE320430T1 (de) Neue kristalline form einer triazolo(4,5- d)pyrimidin-verbindung
IL225893A0 (en) New triazolo pyrimidine compounds
DK1135391T3 (da) Hidtil ukendte triazolo[4,5-d]pyrimidinforbindelser
EE05351B1 (et) Prrolo[2,3-d]primidiinhendid
NO20025977L (no) Imidazopyridin - og imidazopyrimidin antivirale forbindelser
AU3576801A (en) Pyrimidine compounds
DK1087971T3 (da) Pyrrolo[2,3-d]pyrimidinforbindelser
EE200200711A (et) Pürrolo[2,3-d]pürimidiinühendid kui immunosupressiivsed vahendid
CY2015035I1 (el) Ενωσεις πυριμιδινης
DK1087970T3 (da) Pyrrol[2,3-d]pyrimidin forbindelser
ID27127A (id) SENYAWA-SENYAWA TRIAZOLO (4,5-d) PIRIMIDINA YANG BARU
ATE269333T1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-on- und 7-pyridinyl-2,3- dihydroimidazo(1,2-a)pyrimidin-5 1honderivate
ATE231866T1 (de) Pyrazolo(4, 3-d)pyrimidine
PL363077A1 (en) Use of pyrazolo[4,3-d]pyrimidines
PL361890A1 (en) Use of pyrazolo[4,3-d]pyrimidines
DE50103649D1 (de) 2-aminoalkyl-thieno[2,3-d]pyrimidine
DE50106542D1 (de) Substituierte 3,4-dihydro-pyrido[1,2-a]pyrimidine
DE50106048D1 (de) Substituierte 3,4-dihydro-pyrimido [1,2-a]pyrimidine und 3,4-dihydropyrazino [1,2-a]pyrimidine